control in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results GLUCOCOVID, 2020 0.63 [0.25; 1.60]
REMAP-CAP, shock-dependent course, 2020 1.10 [0.58; 2.10]
0.92 [0.54 ; 1.56 ] GLUCOCOVID, 2020, REMAP-CAP, shock-dependent course, 2020 2 0% 304 serious not evaluable death or transfer to ICUdetailed results GLUCOCOVID, 2020 (REV) 1.47 [0.80; 2.71]
1.47 [0.80 ; 2.71 ] GLUCOCOVID, 2020 (REV) 1 0% 63 NA not evaluable deathsdetailed results GLUCOCOVID, 2020 0.63 [0.25; 1.60]
REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53]
0.90 [0.60 ; 1.35 ] GLUCOCOVID, 2020, REMAP-CAP, shock-dependent course, 2020 2 0% 324 serious not evaluable deaths (time to event analysis only)detailed results REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53]
0.98 [0.63 ; 1.53 ] REMAP-CAP, shock-dependent course, 2020 1 0% 260 NA not evaluable clinical improvementdetailed results REMAP-CAP, shock-dependent course, 2020 1.22 [0.76; 1.95]
1.22 [0.76 ; 1.95 ] REMAP-CAP, shock-dependent course, 2020 1 0% 260 NA not evaluable clinical improvement (14-day)detailed results REMAP-CAP, shock-dependent course, 2020 1.03 [0.65; 1.64]
1.03 [0.65 ; 1.64 ] REMAP-CAP, shock-dependent course, 2020 1 0% 260 NA not evaluable death or ventilationdetailed results REMAP-CAP, shock-dependent course, 2020 1.24 [0.55; 2.78]
1.24 [0.55 ; 2.78 ] REMAP-CAP, shock-dependent course, 2020 1 0% 118 NA not evaluable ICU admissiondetailed results GLUCOCOVID, 2020 0.85 [0.27; 2.67]
0.85 [0.27 ; 2.67 ] GLUCOCOVID, 2020 1 0% 64 NA not evaluable serious adverse eventsdetailed results REMAP-CAP, shock-dependent course, 2020 3.68 [0.42; 31.96]
3.68 [0.42 ; 31.96 ] REMAP-CAP, shock-dependent course, 2020 1 0% 242 NA not evaluable 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-08-20 21:45 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 649,650,589,651,968
- roots T: 290